Abstract Three extended release formulations of metoprolol (95 mg metoprolol succinate) with different in vitro release rates were administered to ten healthy males (20–29 years) as single oral doses. The bioavailability properties of the three formulations were evaluated in relation to an intravenous dose (10 mg metoprolol tartrate) and an oral solution (95 mg metoprolol succinate). Both the rate and extent of metoprolol absorption were related to the drug release rate as shown by the plasma concentration-time profiles and resultant pharmacokinetic variables. Individual absorption-time profiles reflected well the corresponding in vitro release curves, showing a good correlation over the entire time interval for all three formulations. For the slowest formulations, drug absorption continued at very delayed times (24–30 h) in most individuals, confirming the good distal gastrointestinal absorption of metoprolol. A reduced bioavailability was seen with all extended release formulations compared with the solution and was probably caused by increased hepatic first-pass metabolism. Incomplete absorption may also contribute to the more markedly reduced bioavailability of the slowest formulation. Evaluation of compartmental (Wagner-Nelson, Loo-Riegelman) and noncompartmental (numerical deconvolution) methods for assessing drug absorption suggests that all three methodologies are appropriate when applied to extended release formulations of metoprolol.
Read full abstract